The possible role of oral contraceptives (OC) in the aetiology of breast cancer has been investigated in numerous epidemiological studies. Most of these studies have indicated that OC use is not associated with any change in breast cancer risk, but there are some residual anxieties about this broad conclusion. In particular, a publication by Paffenberger et al. (1977) suggested the possibility of an adverse effect of OC use before first term pregnancy which was subsequently supported by a study by Pike et al. (1981) . This suggestion, although by no means confirmed, is of particular interest because age at first term pregnancy is known to influence the risk of breast cancer (McMahon et al., 1973) and in consequence some have argued (Day, 1984) that the first term pregnancy may protect against early stage carcinogenesis. Others have suggested that exposure to oestrogens before first term pregnancy may be an important part of the aetiological process (Korenman, 1980) . Drife (1981) , in turn, has hypothesised that irreversible changes in breast tissue associated with pregnancy activate progesterone receptors which then enable the oestrogen exposure to be opposed by circulating progesterone.
The role of OC exposure before first term pregnancy is consequently receiving much epidemiological attention. This is usually in the form of case control studies since cohort studies, which were mostly started in the late sixties, do not include many women who used OC's before first term pregnancy because such use is a relatively recent practice (Bone, 1979) . The results from these studies are conflicting and confusing (McPherson & Drife, 1986) . Some appear to suggest an increased risk associated with long term use before first term pregnancy or before age 25, while others do not. Several possible reasons have been suggested for this, including bias in the selection of controls, bias in recall of OC history and selection bias of cases associated with earlier diagnosis among women who have regular breast examinations. As well as these biases there is the possibility of a differential effect of various OC formulations taken at different times in a womans life and the possibility that there may be a long latent period before the manifestation of any possible effect.
In principle any of these factors could be responsible for the apparently conflicting results. It is, however, difficult to establish with any certainty which actually are, for it is usually only possible to suggest, with varying degrees of plausibility, possible explanations for the different results. We report here the results of a case control study conducted between 1980 and 1984 which was a continuation of a similar (but negative) study conducted between 1968 and 1980 . This enabled us to investigate some of these possible factors with unusual rigour.
Since 1980 the most relevant studies investigating the association between early OC use and breast cancer have been the case control studies of Pike et al. (1983) , Harris et al. (1982) , Rosenberg et al. (1984) , Vessey et al. (1982) , Stadel et al. (1985) , Meirik et al. (1986 and Miller et al. (1986) . Pike et al. (1981) , from Los Angeles, reported an elevated risk for use before first term pregnancy among women under the age of 33, but this was not confirmed by the study of Vessey and colleagues (1982) . Indeed such use appeared, in the latter study, to be protective, but not significantly so. A further extension of Pike's study, published in 1983, appeared to show an elevated risk associated with use before age 25 among women under the age of 37. This, however, was inconsistent with the results of the large American Cancer and Steroid Hormone (CASH) group study published in 1985 (Stadel et al., 1985) . The CASH group found no significant increase in risk either for use before age 25 or for use before first term pregnancy among women under 37 or, in response to the publication of the interim results of the present study , under age 45. Harris et al. (1982) reported an increased risk associated with use before first term pregnancy in a small study, while Rosenberg and colleagues (1984) found no increased risk except in a subgroup exposed for a long period while young, more than ten years before diagnosis. Results from a small study in Southern Sweden (Olson et al., 1985) reported an increased risk associated with starting to use the pill at young ages. However the controls were not interviewed in the same manner as the cases, leading to the possibility of bias.
Most recently, three additional studies have been published, one from Sweden and Norway (Meirik et al., 1986) , another from New Zealand and one from North America (Miller et al., 1986 Clearly since breast cancer is the commonest cancer among women (OPCS, 1982) and since OC use is a very popular method of contraception (Kay, 1986) (Vessey et al., 1982) was, however, changed a little from being largely concerned with the possible effects of contraception to being primarily concerned with fertility and its role in breast cancer aetiology. However, since fertility cannot be directly measured by interview techniques we again sought details of contraceptive practices, and obstetric events as well as conception intentions. In the previous (but not the present) study, controls were matched with cases for parity as well as age and hospital.
When, in 1983, the paper from Los Angeles was published We use standard methods for the analysis of matched case control studies (Breslow & Day, 1980) , adjusting for confouding variables where necessary. When standardizing for the effect of age at first term birth, nullipara were analysed in a separate stratum. Table II shows the results of multiple logistic analysis of total OC use by age group, both crude and after adjusting for possible confouding effects. None of the relative risks is statistically significant but there is a slight suggestion of an increasing risk associated with very long term use in the younger age group, when adjusted for confouding.
Results

General epidemiologicalfindings
In Table III we show similar analyses for the under 45 year olds including only OC use before first term pregnancy. In this instance the results indicate a significantly raised risk associated with increasing duration of use. The x2 value for linear trend (6.96) is highly significant statistically, (P<0.01).
Investigation ofpossible explanations for results
Since the results in the women aged under 45 years are importantly different from those we have already published from an earlier case control study (Vessey et al., 1982) , and from the results of the CASH study (Stadel et al., 1985) and others, we investigated particular hypotheses which might explain these differences. We regard it as being intrinsically unlikely that bias in recall of OC history and bias in the selection of controls could explain much of the difference between our two studies because, for women under the age of 45, they were conducted by the same interviewers in the same hospitals using almost the same protocol for interviewing and control selection, although matching for parity was not undertaken in the more recent study. We have, however, investigated both possibilities. First, Table IV shows a break down of exposure before first term pregnancy among our subjects according to whether they were interviewed before the publication, in October 1983, of the paper by Pike et al. (1983) which received much publicity, or afterwards. Clearly for recall inaccuracy to be a cause of bias, cases must recall their OC history either more or less reliably than controls and this is most likely to happen when there is considerable awareness of a possible association between OCs and breast cancer. There is no evidence for this effect in these data. Secondly we have investigated the diagnoses of the controls selected in the earlier study and in this study. Table V shows the categorization of these diagnoses in the two studies. It is clear that there are some differences in the control diagnoses, notably a higher proportion of arthritis, other musculoskeletal disorders and skin conditions in the second study. However, a comparison between the exposure of these controls and their matched cases reveals little evidence that the change in risk estimates between the two studies is attributable to differences in the diagnoses of the controls (Table VI (7) 74 (21) 216 (28) 239 (68) 493 (64) 27 (8) 61 (8) 48 (14) 87 (11) 106 (30) 293 (38) 39 (11) 95 (12) 273 (78) 753 (97) 26 (7) 9 (1) 29 (8) 9 (1) 23 (7) 3 (0) 351 122 (35) 120 (34) 89 (25) 20 (6) 590 (76) 101 (13) 70 (9) 13 (2) 567 (73) (17) 758 (98) 8 (1) because, on average, the age at diagnosis might be younger for OC users than for non users (Mant et al., 1987) . We asked all our subjects whether they had practiced breast self examination (BSE), whether they had been taught the technique and whether they had a history of medical breast examination before recruitment. and its association with breast cancer would be both difficult and insecure. We therefore decided simply to examine the data by accumulating months of OC use before first term pregnancy in the cases and controls according to reported pill brand. We then ranked the pill brands according to the difference in accumulated months among cases and among controls. In this way we were able to establish which pill brands were making the greatest contribution to the effect seen in Table III . Two points must be emphasized; first it is known that recollection of pill brand is far from reliable (Coulter et al., 1986) and second the individual pill brand differences are heavily affected by sampling error because they are based on small numbers. Indeed, an important proportion of subjects could not remember sufficiently reliably which brand they had used. The results are shown in Table VIII. The most obvious deducation from this table is that (in the light of the hypotheses mentioned) E-O (ethinyl al., 1986) .
The results of this analysis are shown in Table X from which it can be seen that use of all OCs is not associated with a systematic increase in relative risk with increasing time since exposure. However, dividing the data into the two categories of OCs shown in Table IX yields a different set of results. These are also shown in Table X . It can be seen that for E-O OCs the rise in estimated relative risk starts at about 4 years before diagnosis and reaches a maximum at 10 years. Since many of the more common E-O OCs were not introduced until 1970 or later the analyses after this period are most unreliable. For ME OCs the pattern indicates if anything a protective effect associated with long term use, a long time before diagnosis. This trend is, however, not significant. (Individual tabulations of numbers of cases and controls are not given here but can be obtained on request from the authors).
Nothing can be said from these data, if there is a long latent period, about the particular influence of modern low dose pills on breast cancer risk because these pills were not introduced commonly until the mid 1970's. (Korenman, 1980 OCs became widely and freely available in the UK to unmarried women in the early seventies. Such women will now only be in their thirties and early forties and will be unlikely to have accumulated long term early use more than 5 or 10 years ago. Since the formation of a palpable breast cancer may typically take the best part of twenty years, (i.e. the time for precancerous changes plus the time for a tumour to be diagnosed) it may be too soon to expect to observe a coherent epidemiological relationship (Armenian & Lilienfeld, 1979; .
A parallel might, perhaps, be drawn with young women exposed to radiation from the atomic bombs of Hiroshima and Nagasaki who showed a dose related increase in breast cancer incidence but not until 15-20 years after exposure (Tokunaga et al., 1979) or, equally, with pregnant women exposed to diethylstilboestrol who have been shown to have twice the ultimate breast cancer risk compared with unexposed controls (with a follow-up extending to forty years), but in whom no differences were observed until 22 years after exposure (Greenberg et al., 1984) . In the light of the evidence reported here the overall results for long term use before first pregnancy may be regarded as suggestive of an effect.
It is, therefore, important to look for clues as early as possible so that hypotheses suggested in one study as an explanation for the diverse epidemiological results, can be closely, quickly and independently investigated in others. For this reason we have drawn attention to our findings which suggest (but not strongly) a possible effect modification by synthetic oestrogen type. The data also suggest (but not strongly) a latent interval of at least ten years for E-O pills between long term early exposure and an increased risk of breast cancer diagnosis. However, the nature of these findings is such that they should be taken as hypothesis generating, as opposed to hypothesis testing. A priori, both pill type and latency could plausibly be related to the apparent discrepancies in published epidemiological results. However, we decided to divide pill types into those containing E-O and those containing ME because this was the simplest data derived categorization we could make. We are, nonetheless, impressed by the fact that the chi square value in Table X for E-O pills did not diminish, in spite of decreasing numbers as the exclusion period increased. If either of these hypotheses is true, then the power with which they can be reliably detected even in very large studies is currently limited. All recent studies lack adequate precision for detecting a latent effect, for in this study, for instance, only two cases and one control had been exposed for more than 4 years before first term pregnancy more than 15 years before diagnosis. Moreover pill type is probably poorly recalled in the distant past and attention to any subgroup of OCs reduces precision still further. If pill use at particular times in a woman's life, for example when anovulatory cycles are more common, is also important then such complications reduces precision yet again. It is therefore essential to pool data from different studies taking these aspects of pill use into account.
When these results are compared with those we have published previously from a similar case-control study (Vessey et al., 1982) but which was negative, the following differences should be born in mind. First, recruitment to the earlier study was completed in 1980 so there was a relatively short maximum time between first OC exposure and diagnosis. Secondly, early OC use was less common in the Sixties than in the Seventies. Accordingly, long durations of OC use before first term pregnancy were much less common in the first study. In the earlier study, 13% of cases and controls under the age of 40 had used OCs before first term pregnancy, compared with 44% in this study. Moreover, of this use in the earlier study 2% was for more than a year more than ten years before diagnosis (or the equivalent date for controls) compared with 11% in this study. Finally, in the first study a larger proportion of such OC use was of ME pills, because these were more common in the 1960's.
The notion of a latent effect is consistent with the known epidemiology of breast cancer and with the observed effect of radiation and diethylstilboestrol exposure. However, the possibility of a different effect of the two synthetic oestrogens has little basis in either theory or in empirical observation. Mestranol is demethylated to E-O (Bolt et al., 1974) which could give rise to lower peak plasma concentrations of active oestrogen in women taking ME containing pills than in those taking E-O containing pills (Orme et al., 1983) . Conceivably this could explain their lesser effect on breast cancer risk. It is just as likely, however, that the effect is a consequence of ME and E-O being correlated with some other aspect of pill composition. More endocrinological work is required, as well as observational confirmation before any action is taken on these findings. It should be noted that none of our data directly incriminate modern low dose E-O containing pills in any case.
Taking our results together with the extent of the bias that can be a consequence of plausible latent intervals ) and a possible effect modification of pill type, it is possible that epidemiological studies are emerging with consistent results. Young women in the US apparently started using OCs around five years later than their British counterparts (Anonymous, 1985) and a much higher porportion of OCs in the CASH study contained mestranol (Sattin et al., 1986) .
We need to know whether these suggestions can be refuted by other well conducted studies. In particular studies can only now be begun among women with a relatively high risk of breast cancer with a substantial amount of early OC use, sufficiently long ago. While it is clear that the latency argument cannot easily explain the difference between our latest results and the study from New Zealand ) it remains unclear whether or not some aspect of pill type or formulation might not be the explanation. The Scandinavian workers investigated a latent effect but their analyses, which seemed to show no evidence for such an effect, is not conclusive (McPherson & Drife, 1986) . This is because they investigated only time since first use, which is clearly correlated with a possible latent period associated with a particular exposure, but does not measure it. Moreover, they adjusted for total OC exposure in their analysis which might adjust out a latent effect because duration of exposure likewise will be correlated with any latent period. Recent correspondence suggests that the differences observed between Norway and Sweden could be attributed to more recent early use in Norway (Ronstam & Olson, 1987) .
The best way to proceed is to investigate some of these hypotheses in independent data sets, to continue with the assiduous collection of epidemiological data in which contraceptive histories are carefully recorded and, as far as possible, validated and to pool all data sets as soon as is feasible . It 
